tinidazole has been researched along with Indigestion in 31 studies
Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.
tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 9.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 9.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "In a randomized, multicentre, prospective study, a total of 352 patients with duodenal ulcer or non-ulcer dyspepsia were randomly divided into three groups according to the administered regimen: OAC250 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 250 mg), OAC500 group (omeprazole, 20 mg, amoxicillin, 1000 mg, and clarithromycin, 500 mg) and OTC group (omeprazole, 20 mg, tinidazole, 500 mg, and clarithromycin, 500 mg)." | 5.10 | Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication. ( Ahn, DS; Choi, IJ; Choi, KW; Chung, IS; Chung, JM; Hong, WS; Jung, HC; Kim, JH; Lee, SI; Rew, JS; Rhee, JC; Yang, US, 2002) |
| " pylori-positive patients with endoscopically defined peptic ulcer [DU (n = 65), GU (n = 12)] or non-ulcer dyspepsia (NUD, n = 43) were randomized to receive a 1-week course of twice daily omeprazole 20 mg, clarithromycin 250 mg and either metronidazole 400 mg (OCM) or tinidazole 500 mg (OCT) in a double-blind fashion." | 5.09 | Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia. ( Goddard, AF; Lawes, S; Logan, RP; Spiller, RC, 1999) |
| "To evaluate the efficacy of 1-week triple therapy with omeprazole, clarithromycin,and tinidazole (OCT) in Helicobacter pylori-positive older patients with dyspepsia." | 5.09 | The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia. ( Arber, N; Brill, S; Halpern, Z; Konikoff, FM; Moshkowitz, M; Reif, S, 1999) |
| "This study was undertaken to compare the efficacy of lansoprazole (LAN)-based triple therapy with that of RBC-based dual therapy in H pylori-infected patients with duodenal ulcer." | 5.09 | Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study. ( Belmonte, A; Cavaliere, C; Ciliberto, E; Fiocca, R; Frandina, C; Giglio, A; Luzza, F; Pallone, F; Saccà, N; Trimboli, V, 2001) |
| "In a prospective study, 113 patients with peptic ulcer (n = 36) or non-ulcer dyspepsia (n = 77) were randomized to receive 1-wk treatment, composed of omeprazole 20 mg b." | 5.08 | Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study. ( Attili, AF; Diana, F; Pugliano, F; Rinaldi, V; Zullo, A, 1997) |
| " In triple therapy, two studies used the same regimen in nonulcer dyspepsia patients: lansoprazole 30 mg/day for 2 weeks, amoxicillin 2 g/day for 2 weeks, and tinidazole 1 g/day for 2 weeks." | 4.78 | Effect of lansoprazole on Helicobacter pylori. ( Lamouliatte, H, 1993) |
| " Those who tested positive for giardiasis (Group 1) were assigned to receive Tinidazole 2." | 3.79 | Giardia intestinalis in patients with nonulcer dyspepsia. ( Abulhasan, M; Albadry, A; Eida, M; Elshazly, TA, 2013) |
| " pylori strain (34 duodenal ulcer and 37 nonulcer dyspepsia) received omeprazole 40 mg o." | 3.70 | Weekend therapy for the treatment of Helicobacter pylori infection. ( Agosti, R; Bocus, P; Caletti, G; Grigioni, WF; Mazzoni, C; Orcioni, GF; Paparo, GF; Poli, L; Sottili, S; Togliani, T; Tucci, A, 1998) |
| "Sixty three children with dyspepsia (mean age 12 years, range one to 18, M/F 41/22) were Helicobacter pylori positive by histology of gastric antral biopsy specimens and were treated with a six week course of amoxycillin (50 mg/kg) and tinidazole (20 mg/kg)." | 3.68 | Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole. ( Ainley, C; Altare, F; Ansaldi, N; Holton, J; Oderda, G; Osborn, J; Vaira, D, 1992) |
| " Twenty-four patients experienced side-effects, but in only seven cases was treatment discontinued due to adverse events." | 2.69 | Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. ( Bazzoli, F; Cannizzaro, O; D'Angelo, A; Ederle, A; Fossi, S; Gerace, G; Iaquinto, G; Olivieri, A; Pozzato, P; Reina, G; Ricciardiello, L; Roda, E; Scarpulla, G; Spadaccini, A; Tosatto, R; Zagari, M, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 12 (38.71) | 18.2507 |
| 2000's | 16 (51.61) | 29.6817 |
| 2010's | 3 (9.68) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zullo, A | 5 |
| Scaccianoce, G | 1 |
| De Francesco, V | 6 |
| Ruggiero, V | 1 |
| D'Ambrosio, P | 1 |
| Castorani, L | 1 |
| Bonfrate, L | 1 |
| Vannella, L | 1 |
| Hassan, C | 3 |
| Portincasa, P | 1 |
| Abulhasan, M | 1 |
| Elshazly, TA | 1 |
| Eida, M | 1 |
| Albadry, A | 1 |
| Chan, CC | 1 |
| Chien, NH | 1 |
| Lee, CL | 1 |
| Yang, YC | 1 |
| Hung, CS | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Gwee, KA | 1 |
| Teng, L | 1 |
| Wong, RK | 1 |
| Ho, KY | 1 |
| Sutedja, DS | 1 |
| Yeoh, KG | 1 |
| Faleo, D | 2 |
| Panella, C | 4 |
| Ierardi, E | 5 |
| Margiotta, M | 2 |
| Vaira, D | 2 |
| Vakil, N | 1 |
| Gatta, L | 1 |
| Ricci, C | 1 |
| Menegatti, M | 1 |
| Tampieri, A | 1 |
| Perna, F | 1 |
| Rinaldi, V | 2 |
| Perri, F | 1 |
| Papadìa, C | 1 |
| Fornari, F | 1 |
| Pilati, S | 1 |
| Mete, LS | 1 |
| Merla, A | 1 |
| Potì, R | 1 |
| Marinone, G | 1 |
| Savioli, A | 1 |
| Campo, SM | 1 |
| Miglioli, M | 1 |
| Morini, S | 3 |
| Neri, M | 1 |
| Milano, A | 1 |
| Laterza, F | 1 |
| Di Bonaventura, G | 1 |
| Piccolomini, R | 1 |
| Caldarella, MP | 1 |
| Balatsinou, C | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Toracchio, S | 1 |
| Marzio, L | 1 |
| Marangi, S | 1 |
| Burattini, O | 1 |
| Berloco, P | 1 |
| Russo, F | 1 |
| Barone, M | 1 |
| Di Leo, A | 1 |
| Minenna, MF | 2 |
| Stoppino, V | 3 |
| Francavilla, A | 1 |
| Della Valle, N | 2 |
| Amoruso, A | 1 |
| Muscatiello, N | 1 |
| Pietrini, L | 1 |
| Winn, S | 1 |
| Monno, R | 1 |
| Nista, EC | 1 |
| Candelli, M | 1 |
| Zocco, MA | 1 |
| Cazzato, IA | 1 |
| Cremonini, F | 1 |
| Ojetti, V | 2 |
| Santoro, M | 1 |
| Finizio, R | 1 |
| Pignataro, G | 1 |
| Cammarota, G | 3 |
| Gasbarrini, G | 3 |
| Gasbarrini, A | 2 |
| Ford, AC | 1 |
| Forman, D | 2 |
| Nathan, J | 2 |
| Crocombe, WD | 1 |
| Axon, AT | 3 |
| Moayyedi, P | 3 |
| Lamouliatte, H | 1 |
| Ashorn, M | 1 |
| Ruuska, T | 1 |
| Karikoski, R | 1 |
| Miettinen, A | 1 |
| Mäki, M | 1 |
| Tursi, A | 1 |
| Montalto, M | 1 |
| Papa, A | 1 |
| Veneto, G | 1 |
| Cuoco, L | 1 |
| Trua, F | 1 |
| Branca, G | 1 |
| Fedeli, G | 1 |
| Pugliano, F | 1 |
| Diana, F | 1 |
| Attili, AF | 1 |
| Tucci, A | 1 |
| Poli, L | 1 |
| Paparo, GF | 1 |
| Bocus, P | 1 |
| Togliani, T | 1 |
| Mazzoni, C | 1 |
| Orcioni, GF | 1 |
| Agosti, R | 1 |
| Grigioni, WF | 1 |
| Sottili, S | 1 |
| Caletti, G | 1 |
| Parente, F | 1 |
| Imbesi, V | 1 |
| Maconi, G | 1 |
| Cucino, C | 1 |
| Manzionna, G | 1 |
| Vago, L | 1 |
| Bianchi Porro, G | 1 |
| Ricciardiello, L | 1 |
| Cannizzaro, O | 2 |
| D'Angelo, A | 1 |
| Ederle, A | 1 |
| Gerace, G | 1 |
| Iaquinto, G | 1 |
| Reina, G | 1 |
| Scarpulla, G | 1 |
| Spadaccini, A | 1 |
| Olivieri, A | 1 |
| Tosatto, R | 1 |
| Fossi, S | 1 |
| Pozzato, P | 1 |
| Zagari, M | 1 |
| Bazzoli, F | 1 |
| Roda, E | 1 |
| Cestari, R | 1 |
| Goddard, AF | 1 |
| Logan, RP | 1 |
| Lawes, S | 1 |
| Spiller, RC | 1 |
| Moshkowitz, M | 1 |
| Brill, S | 1 |
| Konikoff, FM | 1 |
| Reif, S | 1 |
| Arber, N | 1 |
| Halpern, Z | 1 |
| Cianci, R | 1 |
| Pastorelli, A | 1 |
| Armuzzi, A | 1 |
| Gentiloni, N | 1 |
| Pirozzi, G | 1 |
| Feltbower, R | 2 |
| Brown, J | 2 |
| Mason, S | 2 |
| Mason, J | 2 |
| Richards, ID | 1 |
| Dowell, AC | 1 |
| Testoni, PA | 1 |
| Bagnolo, F | 1 |
| Luzza, F | 1 |
| Giglio, A | 1 |
| Ciliberto, E | 1 |
| Belmonte, A | 1 |
| Cavaliere, C | 1 |
| Saccà, N | 1 |
| Frandina, C | 1 |
| Fiocca, R | 1 |
| Trimboli, V | 1 |
| Pallone, F | 1 |
| Choi, IJ | 1 |
| Jung, HC | 1 |
| Choi, KW | 1 |
| Kim, JH | 1 |
| Ahn, DS | 1 |
| Yang, US | 1 |
| Rew, JS | 1 |
| Lee, SI | 1 |
| Rhee, JC | 1 |
| Chung, IS | 1 |
| Chung, JM | 1 |
| Hong, WS | 1 |
| Duffett, S | 1 |
| Drummond, M | 1 |
| Crocombe, W | 1 |
| Adeyemi, EO | 1 |
| Fadlalla, H | 1 |
| al-Homsi, M | 1 |
| Nnalue, NA | 1 |
| Goodwin, S | 1 |
| Boehme, D | 1 |
| Sim, AJ | 1 |
| Oderda, G | 1 |
| Ainley, C | 1 |
| Holton, J | 1 |
| Osborn, J | 1 |
| Altare, F | 1 |
| Ansaldi, N | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| High Eradication Rates of Helicobacter Pylori With a New Sequential Treatment[NCT00132171] | Phase 3 | 1,000 participants | Interventional | 2001-01-31 | Completed | ||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection[NCT00455806] | Phase 3 | 132 participants | Interventional | 2007-01-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
1 review available for tinidazole and Indigestion
| Article | Year |
|---|---|
Effect of lansoprazole on Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Helicoba | 1993 |
22 trials available for tinidazole and Indigestion
| Article | Year |
|---|---|
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dose-Response Relationship, Drug; | 2013 |
The response of Asian patients with functional dyspepsia to eradication of Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Double-Blind Method; | 2009 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
High eradication rates of Helicobacter pylori with a new sequential treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Therapy, | 2003 |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2003 |
Sequential treatment for Helicobacter pylori does not share the risk factors of triple therapy failure.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2004 |
Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Benz | 2004 |
The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2004 |
Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Aza Compounds; Drug Therapy, Combination; Dyspepsia; Esomeprazole; Female; Fluor | 2005 |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use.
Topics: Adult; Alkylating Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Ana | 2007 |
Low-dose omeprazole plus clarithromycin and either tinidazole or amoxycillin for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 1996 |
Omeprazole plus clarithromycin and either tinidazole or tetracycline for Helicobacter pylori infection: a randomized prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 1997 |
Effects of Helicobacter pylori eradication on gastric function indices in functional dyspepsia. A prospective controlled study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsi | 1998 |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1998 |
Ranitidine bismuth citrate (RBC) based triple therapy for 7 days is more effective than RBC plus clarithromycin for 14 days in dyspeptic patients with Helicobacter pylori infection. H. Pylori Lombardy Group.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Fe | 1998 |
Randomized controlled comparison of nitroimidazoles for the eradication of Helicobacter pylori and relief of ulcer-associated and non-ulcer dyspepsia.
Topics: Adult; Aged; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Dyspeps | 1999 |
The efficacy of omeprazole-based short-term triple therapy in Helicobacter pylori-positive older patients with dyspepsia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithr | 1999 |
Five-day regimens containing ranitidine bismuth citrate plus high-dose clarithromycin and either amoxycillin or tinidazole for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug T | 2000 |
Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.
Topics: Adult; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 2000 |
In dyspeptic patients without gastric phase III of the migrating motor complex, Helicobacter pylori eradication produces no short-term changes in interdigestive motility pattern.
Topics: Administration, Oral; Adult; Analysis of Variance; Biopsy, Needle; Breath Tests; Clarithromycin; Dru | 2000 |
Lansoprazole-based triple therapy versus ranitidine bismuth citrate-based dual therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer: a multicenter, randomized, double-dummy study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Bismuth; Clarit | 2001 |
Efficacy of low-dose clarithromycin triple therapy and tinidazole-containing triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 2002 |
The cost-effectiveness of population Helicobacter pylori screening and treatment: a Markov model using economic data from a randomized controlled trial.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Dyspepsia; Female; Health Care | 2002 |
8 other studies available for tinidazole and Indigestion
| Article | Year |
|---|---|
Giardia intestinalis in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Antiprotozoal Agents; Drug Therapy, Combination; Duodenum; Dyspepsia; Enzyme-Link | 2013 |
Comparison of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori eradication in inactive peptic ulcer disease and the efficiency of sequential therapy in inactive peptic ulcer disease and non-ulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2015 |
Sequential eradicating therapy: a treatment that does not discriminate Helicobacter pylori strains in patients with nonulcer dyspepsia?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Anti | 2002 |
Primary and secondary antibiotic resistance of Helicobacter pylori strains isolated in central Italy during the years 1998-2002.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agen | 2003 |
Helicobacter pylori gastritis in dyspeptic children. A long-term follow-up after treatment with colloidal bismuth subcitrate and tinidazole.
Topics: Adolescent; Biomarkers; Child; Child, Preschool; Drug Therapy, Combination; Dyspepsia; Female; Follo | 1994 |
Weekend therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sc | 1998 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Micr | 1992 |
Eighteen month follow up of Helicobacter pylori positive children treated with amoxycillin and tinidazole.
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Drug Therapy, Combination; Dyspepsia; Female; Foll | 1992 |